Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, ph... by Herbst, Roy S, MD, Redman, Mary W, PhD, Kim, Edward S, MD, Semrad, Thomas J, MD, Bazhenova, Lyudmila, MD, Masters, Gregory, MD, Oettel, Kurt, MD, Guaglianone, Perry, MD, Reynolds, Christopher, MD, Karnad, Anand, MD, Arnold, Susanne M, MD, Varella-Garcia, Marileila, PhD, Moon, James, MS, Mack, Philip C, PhD, Blanke, Charles D, MD, Hirsch, Fred R, MD, Kelly, Karen, MD, Gandara, David R, MD

Get full text

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study by Yang, James Chih-Hsin, MD, PhD, Reckamp, Karen L., MD, Kim, Young-Chul, MD, PhD, Novello, Silvia, MD, PhD, Smit, Egbert F., MD, PhD, Lee, Jong-Seok, MD, PhD, Su, Wu-Chou, MD, Akerley, Wallace L., MD, Blakely, Collin M., MD, PhD, Groen, Harry J.M., MD, PhD, Bazhenova, Lyudmila, MD, Carcereny Costa, Enric, MD, Chiari, Rita, MD, PhD, Hsia, Te-Chun, MD, PhD, Golsorkhi, Tony, MD, Despain, Darrin, MStat, Shih, Danny, BA, Popat, Sanjay, BSc, MBBS, FRCP, PhD, Wakelee, Heather, MD

Get full text

Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial by Gettinger, Scott N, Dr, Bazhenova, Lyudmila A, Prof, Langer, Corey J, Prof, Salgia, Ravi, Prof, Gold, Kathryn A, MD, Rosell, Rafael, Prof, Shaw, Alice T, MD, Weiss, Glen J, MD, Tugnait, Meera, PhD, Narasimhan, Narayana I, PhD, Dorer, David J, PhD, Kerstein, David, MD, Rivera, Victor M, PhD, Clackson, Timothy, PhD, Haluska, Frank G, MD, Camidge, David Ross, Prof

Get full text

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study by Goss, Glenwood, Dr Prof, Tsai, Chun-Ming, Prof, Shepherd, Frances A, Prof, Bazhenova, Lyudmila, Prof, Lee, Jong Seok, MD, Chang, Gee-Chen, MD, Crino, Lucio, MD, Satouchi, Miyako, MD, Chu, Quincy, MD, Hida, Toyoaki, MD, Han, Ji-Youn, Prof, Juan, Oscar, MD, Dunphy, Frank, Prof, Nishio, Makoto, MD, Kang, Jin-Hyoung, MD, Majem, Margarita, MD, Mann, Helen, MSc, Cantarini, Mireille, MD, Ghiorghiu, Serban, MD, Mitsudomi, Tetsuya, Prof

Get full text

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials by Doebele, Robert C, MD, Drilon, Alexander, MD, Paz-Ares, Luis, MD, Siena, Salvatore, Prof, Shaw, Alice T, Prof, Farago, Anna F, MD, Blakely, Collin M, MD, Seto, Takashi, MD, Cho, Byung Chul, Prof, Tosi, Diego, MD, Besse, Benjamin, MD, Chawla, Sant P, MD, Bazhenova, Lyudmila, Prof, Krauss, John C, MD, Chae, Young Kwang, MD, Barve, Minal, MD, Garrido-Laguna, Ignacio, MD, Liu, Stephen V, MD, Conkling, Paul, MD, John, Thomas, MD, Fakih, Marwan, Prof, Sigal, Darren, MD, Loong, Herbert H, MD, Buchschacher, Gary L, MD, Garrido, Pilar, MD, Nieva, Jorge, MD, Steuer, Conor, MD, Overbeck, Tobias R, MD, Bowles, Daniel W, MD, Fox, Elizabeth, MD, Riehl, Todd, PharmD, Chow-Maneval, Edna, PhD, Simmons, Brian, PharmD, Cui, Na, PhD, Johnson, Ann, MS, Eng, Susan, PharmD, Wilson, Timothy R, PhD, Demetri, George D, Prof

Get full text

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials by Gettinger, Scott N., MD, Huber, Rudolf M., MD, Kim, Dong-Wan, XX, Bazhenova, Lyudmila, XX, Hansen, Karin Holmskov, XX, Tiseo, Marcello, XX, Langer, Corey J., XX, Paz-Ares Rodríguez, Luis G., XX, West, Howard L., XX, Reckamp, Karen L., XX, Weiss, Glen J., XX, Smit, Egbert F., XX, Hochmair, Maximilian J., XX, Kim, Sang-We, XX, Ahn, Myung-Ju, XX, Kim, Edward S., XX, Groen, Harry J.M., XX, Pye, Joanna, XX, Liu, Yuyin, XX, Zhang, Pingkuan, XX, Vranceanu, Florin, XX, Camidge, D. Ross, XX

Get full text